{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:13:53Z","timestamp":1780496033355,"version":"3.54.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Ba\u015fkent University Institutional Review Board","award":["DA19\/29"],"award-info":[{"award-number":["DA19\/29"]}]},{"name":"Ba\u015fkent University Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the in vitro activity of plazomicin and two older aminoglycosides (gentamicin and amikacin) against 180 isolates of Escherichia coli and Klebsiella pneumoniae, including subsets of 60 non-ESBL-producing, 60 ESBL-producing and 60 carbapenem-resistant (46 carrying blaOXA-48, 11 carrying blaNDM and 3 carrying blaOXA-48 and blaNDM) strains.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MICs of plazomicin, gentamicin and amikacin were determined by a gradient diffusion method. Gentamicin and amikacin MICs were interpreted according to CLSI criteria and EUCAST breakpoint tables. Plazomicin MICs were interpreted using FDA-defined breakpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All non-ESBL-producing and ESBL-producing isolates were susceptible to plazomicin. The plazomicin susceptibility rate (71.7%) in carbapenem-resistant isolates was significantly higher than those observed for gentamicin (45%) and amikacin (56.7% and 51.7% according to CLSI and EUCAST breakpoints, respectively). Gentamicin, amikacin and plazomicin susceptibility rates (35.6% for gentamicin; 44.4% and 37.8% for amikacin according to CLSI and EUCAST breakpoints, respectively; 64.4% for plazomicin) in carbapenem-resistant K. pneumoniae were significantly lower than those observed for carbapenem-resistant E. coli isolates (73.3% for gentamicin; 93.3% for amikacin and plazomicin). Gentamicin, amikacin and plazomicin susceptibility rates for blaNDM-positive isolates were lower than those observed for blaOXA-48-positive isolates, but differences were not statistically significant. Among the isolates that were non-susceptible to both gentamicin and amikacin, the plazomicin susceptibility rate was less than 30%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although plazomicin showed excellent in vitro activity against carbapenem-susceptible isolates, the plazomicin resistance rate increased to 35.6% among carbapenem-resistant K. pneumoniae and further increased to 45.5% among blaNDM-positive isolates.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab331","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:16:51Z","timestamp":1631099811000},"page":"3192-3196","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of <i>in vitro<\/i> activities of plazomicin and other aminoglycosides against clinical isolates of <i>Klebsiella pneumoniae<\/i> and <i>Escherichia coli<\/i>"],"prefix":"10.1093","volume":"76","author":[{"given":"Gizem","family":"\u0130nce","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Ba\u015fkent University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan Cenk","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Ba\u015fkent University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"\u00dcsk\u00fcdar G\u00fc\u00e7l\u00fc","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Ba\u015fkent University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hale","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Ba\u015fkent University Faculty of Medicine, Adana Medical and Research Center, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7i\u011fdem","family":"Erol","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Ba\u015fkent University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ba\u015fustao\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Ba\u015fkent University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"2021111722580646300_dkab331-B1","doi-asserted-by":"crossref","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: an overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2021111722580646300_dkab331-B2","doi-asserted-by":"crossref","first-page":"e01989-17","DOI":"10.1128\/AAC.01989-17","article-title":"A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis","volume":"62","author":"Connolly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111722580646300_dkab331-B3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2018.10.023","article-title":"In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions","volume":"94","author":"Castanheira","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021111722580646300_dkab331-B4","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.02744-13","article-title":"In vitro activity of plazomicin against 5,015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011-2012","volume":"58","author":"Walkty","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111722580646300_dkab331-B5","first-page":"3346","article-title":"Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms","volume":"73","author":"Castanheira","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021111722580646300_dkab331-B6","doi-asserted-by":"crossref","first-page":"115092","DOI":"10.1016\/j.diagmicrobio.2020.115092","article-title":"Comparative in vitro activity of plazomicin and older aminoglycosides against Enterobacterales isolates; prevalence of aminoglycoside modifying enzymes and 16S rRNA methyltransferases","volume":"97","author":"G\u00fcr","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021111722580646300_dkab331-B7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"key":"2021111722580646300_dkab331-B8","doi-asserted-by":"crossref","first-page":"e01711-19","DOI":"10.1128\/AAC.01711-19","article-title":"In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug-resistant aerobic Gram-negative bacilli","volume":"64","author":"Fleischmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111722580646300_dkab331-B9","doi-asserted-by":"crossref","first-page":"ofz123","DOI":"10.1093\/ofid\/ofz123","article-title":"Plazomicin is active against metallo-\u03b2-lactamase-producing Enterobacteriaceae","volume":"6","author":"Serio","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021111722580646300_dkab331-B10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12879-019-3801-1","article-title":"Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance","volume":"19","author":"Galani","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2021111722580646300_dkab331-B11"},{"key":"2021111722580646300_dkab331-B12","year":"2020"},{"key":"2021111722580646300_dkab331-B13","year":"2021"},{"key":"2021111722580646300_dkab331-B14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021111722580646300_dkab331-B15","first-page":"319","article-title":"Arising prevalence of OXA-48 producer Escherichia coli and OXA-48 with NDM co-producer Klebsiella pneumoniae strains","volume":"27","author":"Uskudar-Guclu","year":"2019","journal-title":"Rev Romana Med Lab"},{"key":"2021111722580646300_dkab331-B16"},{"key":"2021111722580646300_dkab331-B17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jac\/dkt078","article-title":"Association of the novel aminoglycoside resistance determinant RmtF with NDM carbapenemase in Enterobacteriaceae isolated in India and the UK","volume":"68","author":"Hidalgo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021111722580646300_dkab331-B18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2018.03.016","article-title":"High prevalence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacteriaceae in the UK and Ireland","volume":"52","author":"Taylor","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2021111722580646300_dkab331-B19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2017.11.004","article-title":"Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers","volume":"90","author":"Martins","year":"2018","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/12\/3192\/41136407\/dkab331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/12\/3192\/41136407\/dkab331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T23:03:35Z","timestamp":1637190215000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/12\/3192\/6367822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,9,9]]},"published-print":{"date-parts":[[2021,11,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab331","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,9,9]]}}}